VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT’s) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Pineda-Roman, M, Zangari, M, van Rhee, F, Anaissie, E, Szymonifka, J, Hoering, A, Petty, N, Crowley, J, Shaughnessy, J, Epstein, J, Barlogie, B
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2008
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664925/
https://ncbi.nlm.nih.gov/pubmed/18432260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2008.99
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk